Charles N. de Leeuw

Charles N. de Leeuw

Auto-generated profile, based on publicly available information

Charles N. de Leeuw

Department of Neurological Surgery, Oregon Health & Science University, Portland, OR, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2012 in Genome Biology
Verified
Journal Article
Open access
PDF file
DYDimas Yusuf
Dimas Yusuf
SBStefanie L Butland
Stefanie L Butland
MSMagdalena I Swanson
Magdalena I Swanson
EBEugene Bolotin
Eugene Bolotin
ATAmy Ticoll
Amy Ticoll
WWWyeth W Wasserman
Wyeth W Wasserman
Here we present the Transcription Factor Encyclopedia (TFe), a new web-based compendium of mini review articles on transcription factors (TFs) that is founded on the principles of open access and collaboration. Our consortium of over 100 researchers has collectively contributed over 130 mini review articles on pertinent human, mouse and rat TFs. Notable features of the TFe website include a high-quality PDF generator and web API for programmatic data retrieval. TFe aims to rapidly educate scientists about the TFs they encounter through the delivery of succinct summaries written and vetted by experts in the field. TFe is available at http://www.cisreg.ca/tfe.

15 October 2018 in Neuro-Oncology
Verified
Journal Article
Closed access
CLCharles N de Leeuw
Charles N de Leeuw
MVMichael A Vogelbaum
Michael A Vogelbaum
Emerging evidence suggests survival benefit from resection beyond all MRI abnormalities present on T1-enhanced and T2‒fluid attenuated inversion recovery (FLAIR) modalities in glioma (supratotal resection); however, the quality of evidence is unclear. We addressed this question via systematic review of the literature. EMBASE, MEDLINE, Scopus, and Web of Science databases were queried. Case studies, reviews or editorials, non-English, abstract-only, brain metastases, and descriptive works were excluded. All others were included. Three hundred and nine unique references yielded 41 studies for full-text review, with 7 included in the final analysis. Studies were mostly of Oxford Center for Evidence-Based Medicine Level 4 quality. A total of 88 patients underwent supratotal resection in a combined cohort of 492 patients (214 males and 278 females, age 18 to 82 years). Fifty-one supratotal resections were conducted on high-grade gliomas, and 37 on low-grade gliomas. Karnofsky performance status, overall survival, progression-free survival, neurological deficits postoperatively, and anaplastic transformation were the main measured outcomes. No randomized controlled trials were identified. Preliminary low-quality support was found for supratotal resection in increasing overall survival and progression-free survival for both low-grade and high-grade glioma. The literature suggests insufficient evidence for carte blanche application of supratotal resection, particularly in lower-grade gliomas where neurological deficits can result in long-term disability. While the preliminary studies discussed here, containing data from only a few centers, have reported increased progression-free and overall survival, these claims require validation in prospective research studies involving larger patient populations with clearly defined appropriate outcome metrics in order to reduce potential bias.

31 August 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
EPElodie Portales-Casamar
Elodie Portales-Casamar
DSDouglas J. Swanson
Douglas J. Swanson
LLLi Liu
Li Liu
CLCharles N. de Leeuw
Charles N. de Leeuw
KBKathleen G. Banks
Kathleen G. Banks
ESElizabeth M. Simpson
Elizabeth M. Simpson
The Pleiades Promoter Project integrates genomewide bioinformatics with large-scale knockin mouse production and histological examination of expression patterns to develop MiniPromoters and related tools designed to study and treat the brain by directed gene expression. Genes with brain expression patterns of interest are subjected to bioinformatic analysis to delineate candidate regulatory regions, which are then incorporated into a panel of compact human MiniPromoters to drive expression to brain regions and cell types of interest. Using single-copy, homologous-recombination “knockins” in embryonic stem cells, each MiniPromoter reporter is integrated immediately 5′ of the Hprt locus in the mouse genome. MiniPromoter expression profiles are characterized in differentiation assays of the transgenic cells or in mouse brains following transgenic mouse production. Histological examination of adult brains, eyes, and spinal cords for reporter gene activity is coupled to costaining with cell-type–specific markers to define expression. The publicly available Pleiades MiniPromoter Project is a key resource to facilitate research on brain development and therapies.

26 August 2015 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
MSMiranda L. Scalabrino
Miranda L. Scalabrino
SBSanford L. Boye
Sanford L. Boye
KFKathryn M. H. Fransen
Kathryn M. H. Fransen
JNJennifer M. Noel
Jennifer M. Noel
FDFrank M. Dyka
Frank M. Dyka
SBShannon E. Boye
Shannon E. Boye
Adeno-associated virus (AAV) effectively targets therapeutic genes to photoreceptors, pigment epithelia, Müller glia and ganglion cells of the retina. To date, no one has shown the ability to correct, with gene replacement, an inherent defect in bipolar cells (BCs), the excitatory interneurons of the retina. Targeting BCs with gene replacement has been difficult primarily due to the relative inaccessibility of BCs to standard AAV vectors. This approach would be useful for restoration of vision in patients with complete congenital stationary night blindness (CSNB1), where signaling through the ON BCs is eliminated due to mutations in their G-protein-coupled cascade genes. For example, the majority of CSNB1 patients carry a mutation in nyctalopin (NYX), which encodes a protein essential for proper localization of the TRPM1 cation channel required for ON BC light-evoked depolarization. As a group, CSNB1 patients have a normal electroretinogram (ERG) a-wave, indicative of photoreceptor function, but lack a b-wave due to defects in ON BC signaling. Despite retinal dysfunction, the retinas of CSNB1 patients do not degenerate. The Nyxnob mouse model of CSNB1 faithfully mimics this phenotype. Here, we show that intravitreally injected, rationally designed AAV2(quadY-F+T-V) containing a novel ‘Ple155’ promoter drives either GFP or YFP_Nyx in postnatal Nyxnob mice. In treated Nyxnob retina, robust and targeted Nyx transgene expression in ON BCs partially restored the ERG b-wave and, at the cellular level, signaling in ON BCs. Our results support the potential for gene delivery to BCs and gene replacement therapy in human CSNB1.

1 January 2014 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
CLCharles N de Leeuw
Charles N de Leeuw
FDFrank M Dyka
Frank M Dyka
SBSanford L Boye
Sanford L Boye
SLStéphanie Laprise
Stéphanie Laprise
MZMichelle Zhou
Michelle Zhou
ESElizabeth M Simpson
Elizabeth M Simpson
An international, open-access journal publishing top-quality, novel methods and technology development, as well as significant improvements to established techniques in basic, translational, and clinical cell and gene therapy.

1 March 2009 in Genomics
Verified
Journal Article
Closed access
GYG.S. Yang
G.S. Yang
KBK.G. Banks
K.G. Banks
RBR.J. Bonaguro
R.J. Bonaguro
GWG. Wilson
G. Wilson
LDL. Dreolini
L. Dreolini
ESE.M. Simpson
E.M. Simpson